抗艾新药与子公司拉升业绩，艾迪药业去年亏损收窄

Core Viewpoint - Eddie Pharmaceuticals reported a significant revenue increase of 72.49% in 2025, driven by rising income from innovative anti-HIV drugs and operational data from its subsidiary, Nanda Pharmaceuticals. The company's losses narrowed from 141 million yuan in 2024 to 19.73 million yuan in 2025, marking an 86.02% reduction in loss margin [1][2]. Group 1: Financial Performance - The company achieved a revenue of 721 million yuan in 2025, with a year-on-year growth of 72.49% [2]. - The loss for 2025 was reduced to 19.73 million yuan from 141 million yuan in 2024, indicating a significant improvement in financial health [2]. - Eddie Pharmaceuticals turned a profit in operating income for the first time, reporting 47.74 million yuan in 2025 [2]. Group 2: Anti-HIV Drug Segment - Revenue from innovative anti-HIV drugs is projected to reach 285 million yuan in 2025, representing a 90.34% increase year-on-year [3]. - The anti-HIV drugs are expected to account for 39.53% of the company's total revenue in 2025 [3]. - The sales of anti-HIV new drugs nearly doubled from 150 million yuan in 2024 to 285 million yuan in 2025 [3]. Group 3: Nanda Pharmaceuticals Contribution - Nanda Pharmaceuticals, a subsidiary, is expected to generate 300 million yuan in revenue for 2025, reflecting a 227.38% increase year-on-year [4]. - Eddie Pharmaceuticals has made several acquisitions to increase its stake in Nanda Pharmaceuticals, enhancing its control and management efficiency [4][6]. - The strategic focus on Nanda Pharmaceuticals aims to solidify Eddie Pharmaceuticals' position in the human protein sector, particularly in the production of urokinase and other biopharmaceuticals [5][6].